Brineura cerliponase alfa regulatory update

EMA accepted for review an MAA from BioMarin for Brineura cerliponase alfa to treat children with neuronal ceroid lipofuscinosis type 2 (CLN2) disease. The MAA has accelerated assessment, and BioMarin...